{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:16:37Z","timestamp":1792757797708,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Effective management of chronic kidney disease (CKD) in systemic lupus erythematosus (SLE) is crucial for reducing long-term complications. Sodium\u2013glucose transport 2 inhibitors (SGLT2is) improve renal and cardiovascular outcomes of non-SLE-related CKD. We aimed to assess clinical characteristics and outcomes of SLE patients treated with SGLT2is.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study evaluated adult SLE patients treated with SGLT2is for\u2009\u2265\u20093 months compared to untreated patients. Disease-related characteristics, kidney-related factors, and comorbidities were assessed. Repeated measures analysis model was applied to compare estimated glomerular filtration rate (eGFR) at different timepoints. Additional outcomes included infections, hospitalizations, and all-cause mortality. In SGLT2is-treated patients, eGFR and albuminuria were recorded before SGLT2is initiation, at 1 month, and 1 year following SGLT2is initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 112 consecutive patients were included with a mean follow-up of 18.1\u2009\u00b1\u200912.7 years since SLE diagnosis. The use of SGLT2is in 9 SLE patients showed a stable kidney function over-time (60\u00a0ml\/min\/m\n                      <jats:sup>2<\/jats:sup>\n                      \u2009\u00b1\u200915 before treatment vs. 60\u2009\u00b1\u200917\u00a0ml\/min\/m\n                      <jats:sup>2<\/jats:sup>\n                      at 1\u00a0year of treatment, p\u2009=\u20090.5) and a trend toward reduction in proteinuria (450\u2009\u00b1\u2009637\u00a0mg\/g before treatment to 279\u2009\u00b1\u2009401\u00a0mg\/g at 12\u00a0months following treatment, p\u2009=\u20090.07), without major adverse effects. No significant differences in cardiovascular events, infections, hospitalizations, or mortality rates were observed between treated and untreated patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests a potential benefit of SGLT2is in SLE patients. Further research is needed to confirm the nephro- and cardioprotective effects of SGLT2is in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11255-025-04815-5","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T01:57:05Z","timestamp":1760666225000},"page":"1783-1791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical experience with sodium\u2013glucose transport 2 (SGLT2) inhibitors in patients with systemic lupus erythematosus"],"prefix":"10.1007","volume":"58","author":[{"given":"Oshrat E.","family":"Tayer-Shifman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Benchetrit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorin","family":"Bar-Ziv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Pri-Paz Basson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaye","family":"Kivity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Cohen-Hagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"5","key":"4815_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH (2017) Update on lupus nephritis. Clin J Am Soc Nephrol 12(5):825\u2013835","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4815_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/ndt\/gfad154","volume":"39","author":"JE Rojas-Rivera","year":"2023","unstructured":"Rojas-Rivera JE, Bakkaloglu SA, Bolignano D, Nistor I, Sarafidis PA, Stoumpos S et al (2023) Chronic kidney disease: the missing concept in the 2019 EULAR\/ERA-EDTA recommendations for lupus nephritis. Nephrol Dial Transplant 39(1):151\u2013158","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"4815_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.kint.2016.05.017","volume":"90","author":"HJ Anders","year":"2016","unstructured":"Anders HJ, Rovin B (2016) A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int 90(3):493\u2013501","journal-title":"Kidney Int"},{"issue":"10075","key":"4815_CR4","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P (2017) Chronic kidney disease. Lancet 389(10075):1238\u20131252","journal-title":"Lancet"},{"issue":"4","key":"4815_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004100","volume":"4","author":"HI McDonald","year":"2014","unstructured":"McDonald HI, Thomas SL, Nitsch D (2014) Chronic kidney disease as a risk factor for acute community-acquired infections in high-income countries: a systematic review. BMJ Open 4(4):e004100","journal-title":"BMJ Open"},{"issue":"7","key":"4815_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0961203315627202","volume":"25","author":"YH Lee","year":"2016","unstructured":"Lee YH, Choi SJ, Ji JD, Song GG (2016) Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 25(7):727\u2013734","journal-title":"Lupus"},{"issue":"7","key":"4815_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.autrev.2019.05.011","volume":"18","author":"A Mageau","year":"2019","unstructured":"Mageau A, Timsit JF, Perrozziello A, Ruckly S, Dupuis C, Bouadma L et al (2019) The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study. Autoimmun Rev 18(7):733\u2013737","journal-title":"Autoimmun Rev"},{"issue":"7","key":"4815_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/acr.24552","volume":"74","author":"S Garg","year":"2022","unstructured":"Garg S, Raval AN, Hansen KE, Zhong W, Huang Y, Smith M et al (2022) Association of renal arteriosclerosis with atherosclerotic cardiovascular disease risk in Lupus nephritis. Arthritis Care Res (Hoboken) 74(7):1105\u20131112","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4815_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6691821","volume":"2021","author":"M Mbengue","year":"2021","unstructured":"Mbengue M, Lot ML, Diagne S, Niang A (2021) Proliferative glomerulonephritis: risk factor for hypertension in lupus. Int J Hypertens 2021:6691821","journal-title":"Int J Hypertens"},{"issue":"1","key":"4815_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/1753944716637807","volume":"11","author":"EB Taylor","year":"2016","unstructured":"Taylor EB, Ryan MJ (2016) Understanding mechanisms of hypertension in systemic lupus erythematosus. Ther Adv Cardiovasc Dis 11(1):20\u201332","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"3","key":"4815_CR11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1523-1755.2004.00462.x","volume":"65","author":"DA De Albuquerque","year":"2004","unstructured":"De Albuquerque DA, Saxena V, Adams DE, Boivin GP, Brunner HI, Witte DP et al (2004) An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis. Kidney Int 65(3):846\u2013859","journal-title":"Kidney Int"},{"key":"4815_CR12","doi-asserted-by":"crossref","unstructured":"KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105(1s):S1-s69.","DOI":"10.1016\/j.kint.2023.09.002"},{"issue":"1","key":"4815_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15\u201329","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4815_CR14","first-page":"1085","volume":"17","author":"MM Constantin","year":"2019","unstructured":"Constantin MM, Nita IE, Olteanu R, Constantin T, Bucur S, Matei C et al (2019) Significance and impact of dietary factors on systemic lupus erythematosus pathogenesis. Exp Ther Med 17(2):1085\u20131090","journal-title":"Exp Ther Med"},{"issue":"3","key":"4815_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.amjmed.2022.11.016","volume":"136","author":"C Hurst","year":"2023","unstructured":"Hurst C, Soto M, Vina ER, Rodgers KE (2023) Renin-angiotensin system-modifying antihypertensive drugs can reduce the risk of cardiovascular complications in lupus: a retrospective cohort study. Am J Med 136(3):284\u201393.e4","journal-title":"Am J Med"},{"issue":"1","key":"4815_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0139-5","volume":"5","author":"ZX Xiao","year":"2020","unstructured":"Xiao ZX, Hu X, Zhang X, Chen Z, Wang J, Jin K et al (2020) High salt diet accelerates the progression of murine lupus through dendritic cells via the p38 MAPK and STAT1 signaling pathways. Signal Transduct Target Ther 5(1):34","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"4815_CR17","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"1","key":"4815_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","volume":"94","author":"HJL Heerspink","year":"2018","unstructured":"Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94(1):26\u201339","journal-title":"Kidney Int"},{"issue":"7","key":"4815_CR19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF et al (2024) Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 12(7):447\u2013461","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"4815_CR20","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","volume":"75","author":"CS Wilcox","year":"2020","unstructured":"Wilcox CS (2020) Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. Hypertension 75(4):894\u2013901","journal-title":"Hypertension"},{"issue":"2","key":"4815_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfad175","volume":"39","author":"F Caravaca-Font\u00e1n","year":"2024","unstructured":"Caravaca-Font\u00e1n F, Stevens K, Padr\u00f3n M, Huerta A, Montomoli M, Villa J et al (2024) Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. Nephrol Dial Transplant 39(2):328\u2013340","journal-title":"Nephrol Dial Transplant"},{"key":"4815_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222512","author":"E Morales","year":"2022","unstructured":"Morales E, Galindo M (2022) SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222512","journal-title":"Ann Rheum Dis"},{"key":"4815_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2023.1105676","volume":"3","author":"E Morales","year":"2023","unstructured":"Morales E, Sandino J, Galindo M (2023) Lupus nephropathy beyond immunosuppression: searching for nephro and cardioprotection. Frontiers in nephrology 3:1105676","journal-title":"Frontiers in nephrology"},{"issue":"10","key":"4815_CR24","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1136\/ard-2023-224242","volume":"82","author":"XY Zhao","year":"2023","unstructured":"Zhao XY, Li SS, He YX, Yan LJ, Lv F, Liang QM et al (2023) SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann Rheum Dis 82(10):1328\u20131340","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4815_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/art.43037","volume":"77","author":"KS Ma","year":"2025","unstructured":"Ma KS, Lo JE, Kyttaris VC, Tsokos GC, Costenbader KH (2025) Efficacy and safety of Sodium-glucose cotransporter 2 inhibitors for the primary prevention of cardiovascular, renal events, and safety outcomes in patients with Systemic lupus erythematosus and comorbid type 2 diabetes: a population-based target trial emulation. Arthritis Rheumatol 77(4):414\u2013422","journal-title":"Arthritis Rheumatol"},{"key":"4815_CR26","unstructured":"Sammaritano LR, Askanase A, Bermas BL, Dall'Era M, Duarte-Garc\u00eda A, Hiraki LT, et al. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis rheumatol. 2025."},{"key":"4815_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225248","author":"MJ Soler","year":"2024","unstructured":"Soler MJ, Jacobs Cach\u00e1 C, Anders HJ et al (2024) Correspondence on: \u2018SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy\u2019 by Zhao et al. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2023-225248","journal-title":"Ann Rheum Dis"},{"key":"4815_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002686","author":"H Wang","year":"2022","unstructured":"Wang H, Li T, Sun F, Liu Z, Zhang D, Teng X et al (2022) Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2022-002686","journal-title":"RMD Open"},{"issue":"6","key":"4815_CR29","first-page":"677","volume":"31","author":"JL Teruel Briones","year":"2011","unstructured":"Teruel Briones JL, Gomis Couto A, Sabater J, Fern\u00e1ndez Lucas M, Rodr\u00edguez Mendiola N, Villafruela JJ et al (2011) Validation of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation in advanced chronic renal failure. Nefrologia\u202f: publicacion oficial de la Sociedad Espanola Nefrologia 31(6):677\u2013682","journal-title":"Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia"},{"issue":"6","key":"4815_CR30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.16578","volume":"7","author":"FS Yen","year":"2024","unstructured":"Yen FS, Wang SI, Hsu CC, Hwu CM, Wei JC (2024) Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus. JAMA Netw Open 7(6):e2416578","journal-title":"JAMA Netw Open"},{"key":"4815_CR31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-1087","author":"K Cohen-Hagai","year":"2025","unstructured":"Cohen-Hagai K, Saban M, Benchetrit S, Bar-Ziv D, Nacasch N, Shashar M et al (2025) Prevalence, risk factors, and outcomes of chronic kidney disease in patients with systemic lupus erythematosus with and without lupus nephritis. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.2024-1087","journal-title":"J Rheumatol"},{"key":"4815_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152746","volume":"73","author":"I Sagy","year":"2025","unstructured":"Sagy I, Shitrit I, Abuhasira R, David RB, Haviv YS, Tayer-Shifman O et al (2025) Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: a national cohort study. Semin Arthritis Rheum 73:152746","journal-title":"Semin Arthritis Rheum"},{"key":"4815_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1010693","volume":"9","author":"A Mascolo","year":"2022","unstructured":"Mascolo A, Di Napoli R, Balzano N, Cappetta D, Urbanek K, De Angelis A et al (2022) Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary. Front Cardiovasc Med 9:1010693","journal-title":"Front Cardiovasc Med"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04815-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04815-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04815-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:42:29Z","timestamp":1777297349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04815-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4815"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04815-5","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests. KCH declares having received lecture fees from Boehringer Ingelheim and AstraZeneca","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}